Re-thinking yellow fever vaccines: fighting old foes with new generation vaccines

References

• Douam F, Ploss A. Yellow fever virus: knowledge gaps impeding the fight against an old foe. Trends Microbiol. 2018;26:913–9.
   PubMed Web of Science ®Google Scholar
• Monath TP. Yellow fever: an update. Lancet Infect Dis. 2001;1:11–20.
   PubMedGoogle Scholar
• Staples JE, Monath TP. Yellow fever: 100 years of discovery. JAMA. 2008;300:960–62.
   PubMed Web of Science ®Google Scholar
• Taubenberger JK, Morens DM. 1918 Influenza: the mother of all pandemics. Emerg Infect Dis. 2006;12:15–22.
   PubMed Web of Science ®Google Scholar
• Yellow Fever, 2019 case definition. Atlanta (USA): Centers of Disease Control and Prevention (CDC), 2019 [accessed 2020 Oct 13]. https://wwwn.cdc.gov/nndss/conditions/yellow-fever/case-definition/2019/:NationalNotifiableDiseasesSurveillanceSystem(NNDSS) .
   Google Scholar
• Theiler MSH. The effect of prolonged cultivation in vitro upon the pathogenicity of Yellow fever virus. J Exp Med. 1937;65:767‐86.
   Google Scholar
• Tomori O. Yellow fever: the recurring plague. Crit Rev Clin Lab Sci. 2004;41:391–427.
   PubMed Web of Science ®Google Scholar
• Barrett AD. Yellow fever in angola and beyond–the problem of vaccine supply and demand. N Engl J Med. 2016;375:301–03.
   PubMed Web of Science ®Google Scholar
• Tomashek KM, Challberg M, Nayak SU, Schiltz HF. Disease resurgence, production capability issues and safety concerns in the context of an aging population: is there a need for a new yellow fever vaccine? Vaccines (Basel). 2019;7.
   Web of Science ®Google Scholar
• A global strategy to eliminate Yellow fever epidemics 2017–2026. Geneva (Switzerland): World Health Organization, 2018.
   Google Scholar
• Collins ND, Barrett AD. Live attenuated yellow fever 17D vaccine: a legacy vaccine still controlling outbreaks in modern day. Curr Infect Dis Rep. 2017;19:14.
   PubMed Web of Science ®Google Scholar
• The L. Yellow fever: a global reckoning. Lancet. 2016;387:1348.
   Web of Science ®Google Scholar
• Yellow fever: a current threat. Emergencies preparedness, response. World Health Organization. [accessed 2020 Apr 3]. https://www.who.int/csr/disease/yellowfev/impact1/en/ .
   Google Scholar
• Nathan N, Barry M, Van Herp M, Zeller H. Shortage of vaccines during a yellow fever outbreak in Guinea. Lancet. 2001;358:2129–30.
   PubMed Web of Science ®Google Scholar
• Gardner CL, Ryman KD. Yellow fever: a reemerging threat. Clin Lab Med. 2010;30:237–60.
   PubMed Web of Science ®Google Scholar
• Seligman SJ, Casanova JL. Yellow fever vaccine: worthy friend or stealthy foe? Expert Rev Vaccines. 2016;15:681–91.
   PubMed Web of Science ®Google Scholar
• Delatorre E, De Abreu FVS, Ribeiro IP, Gomez MM, Aac DS, Ferreira-de-brito A, Neves M, Bonelly I, de Miranda RM, Furtado ND, et al. Distinct YFV lineages co-circulated in the Central-Western And Southeastern Brazilian regions from 2015 to 2018. Front Microbiol. 2019;10:1079.
   PubMed Web of Science ®Google Scholar
• Silva NIO, Sacchetto L, De Rezende IM, Trindade GS, LaBeaud AD, De Thoisy B, Drumond BP. Recent sylvatic yellow fever virus transmission in Brazil: the news from an old disease. Virol J. 2020;17:9.
   PubMed Web of Science ®Google Scholar
• Monath TP, Vasconcelos PF. Yellow fever. J Clin Virol. 2015;64:160–73.
   PubMed Web of Science ®Google Scholar
• Visser LG, Roukens AH. Modelling a way out of yellow fever. Lancet. 2016;388:2847–48.
   PubMed Web of Science ®Google Scholar
• Barrett AD, Teuwen DE. Yellow fever vaccine - how does it work and why do rare cases of serious adverse events take place? Curr Opin Immunol. 2009;21:308–13.
   PubMed Web of Science ®Google Scholar
• Van Epps HL. Broadening the horizons for yellow fever: new uses for an old vaccine. J Exp Med. 2005;201:165–68.
   PubMed Web of Science ®Google Scholar
• Silva JVJ Jr., Lopes TRR, Oliveira-Filho EF, Oliveira RAS, Duraes-Carvalho R, Gil L. Current status, challenges and perspectives in the development of vaccines against yellow fever, dengue, Zika and chikungunya viruses. Acta Trop. 2018;182:257–63.
   PubMed Web of Science ®Google Scholar
• Barrett ADT. Yellow fever live attenuated vaccine: a very successful live attenuated vaccine but still we have problems controlling the disease. Vaccine. 2017;35:5951–55.
   PubMed Web of Science ®Google Scholar
• Beck AS, Barrett AD. Current status and future prospects of yellow fever vaccines. Expert Rev Vaccines. 2015;14:1479–92.
   PubMed Web of Science ®Google Scholar
• Contraindications administering yellow fever vaccine. Atlanta (USA): Center of Disease Control. [accessed 2020 May 19]. https://www.cdc.gov/travel-training/local/HistoryEpidemiologyandVaccination/contraindications-administering-yellow-fever-vaccine.pdf .
   Google Scholar
• De Jong W, De Man RA, Dalm V, Reusken C, Goeijenbier M, Van Gorp ECM. Yellow fever vaccination for immunocompromised travellers: unjustified vaccination hesitancy? J Travel Med. 2019;26.
   Web of Science ®Google Scholar
• Porudominsky R, Gotuzzo EH. Yellow fever vaccine and risk of developing serious adverse events: a systematic review. Rev Panam Salud Publica. 2018;42:e75.
   PubMed Web of Science ®Google Scholar
• Monath TP. Yellow fever vaccine. Expert Rev Vaccines. 2005;4.
   Web of Science ®Google Scholar
• Krubiner CB, Schwartz DA. Viral hemorrhagic fevers in pregnant women and the vaccine landscape: comparisons between yellow fever, Ebola, and lassa fever. Curr Trop Med Rep. 2019;6:186–96.
   Google Scholar
• United Nations. Fertility Data. World population prospects 2019. Depeartment of Economic and Social Affairs. Population Dynamics, 2020[accessed 2020 Apr 3]. https://population.un.org/wpp/Download/Standard/Fertility/ .
   Google Scholar
• Q&A: fractional doses of the yellow fever vaccine. World Health Organization, 2017 [accessed 2020 Apr 3]. https://www.who.int/emergencies/yellow-fever/mediacentre/qa-fractional-dosing/en/ .
   Google Scholar
• Yellow fever. International travel and health. World Health Organization. [accessed 2021 Jan 4] https://www.who.int/ith/vaccines/yf/en/#:~:text=The%20YF%20vaccine%20is%20contraindicated,transmission%20may%20be%20very%20high .
   Google Scholar
• Visser LG. The immunosuppressed traveler. Infect Dis Clin North Am. 2012;26:609–24.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Cancer today. International Agency for Research on Cancer, 2020 [accessed 2020 Apr 3]. https://gco.iarc.fr/today/online-analysis-map?v=2018&mode=population&mode_population=continents&population=900&populations=900&key=asr&sex=0&cancer=39&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17items=10&group_cancer=1&include_nmsc=1&include_nmsc_other=1&projection=globe&color_palette=default&map_scale=quantile&map_nb_colors=5&continent=0&rotate=%255B10%252C0%255D .
   Google Scholar
• United Nations. AIDSinfo. UNAIDS, 2020 [accessed 2020 Apr 3]. http://aidsinfo.unaids.org/ .
   Google Scholar
• Colin De Verdiere N, Durier C, Samri A, Meiffredy V, Launay O, Matheron S, Mercier-Delarue S, Even S, Aboulker JP, Molina JM, et al. Immunogenicity and safety of yellow fever vaccine in HIV-1-infected patients. AIDS. 2018;32:2291–99.
   PubMed Web of Science ®Google Scholar
• Dhanapala P, De Silva C, Doran T, Suphioglu C. Cracking the egg: an insight into egg hypersensitivity. Mol Immunol. 2015;66:375–83.
   PubMed Web of Science ®Google Scholar
• Rona RJ, Keil T, Summers C, Gislason D, Zuidmeer L, Sodergren E, Sigurdardottir ST, Lindner T, Goldhahn K, Dahlstrom J, et al. The prevalence of food allergy: a meta-analysis. J Allergy Clin Immunol. 2007;120:638–46.
   PubMed Web of Science ®Google Scholar
• Monath TP, Lee CK, Julander JG, Brown A, Beasley DW, Watts DM, Hayman E, Guertin P, Makowiecki J, Crowell J, et al. Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity. Vaccine. 2010;28:3827–40.
   PubMed Web of Science ®Google Scholar
• Kelso JM, Mootrey GT, Tsai TF. Anaphylaxis from yellow fever vaccine. J Allergy Clin Immunol. 1999;103:698–701.
   PubMed Web of Science ®Google Scholar
• Lindsey NP, Schroeder BA, Miller ER, Braun MM, Hinckley AF, Marano N, Slade BA, Barnett ED, Brunette GW, Horan K, et al. Adverse event reports following yellow fever vaccination. Vaccine. 2008;26:6077–82.
   PubMed Web of Science ®Google Scholar
• Our Wolrd in Data. Population by age bracket with UN projections, World, 1950 to 2020. Oxford Martin School, University of Oxford, 2020 [accessed 2020 Apr 3]. https://ourworldindata.org/population-aged-65-outnumber-children.
   Google Scholar
• Wu JT, Peak CM, Leung GM, Lipsitch M. Fractional dosing of yellow fever vaccine to extend supply: a modelling study. Lancet. 2016;388:2904–11.
   PubMed Web of Science ®Google Scholar
• Monath TP, Woodall JP, Gubler DJ, Yuill TM, Mackenzie JS, Martins RM,Reiter P, Heymann DL. Yellow fever vaccine supply: a possible solution. Lancet. 2016;387:1599–600.
   PubMed Web of Science ®Google Scholar
• Kraus B, Von Fircks S, Feigl S, Koch SM, Fleischanderl D, Terler K,Dersch-Pourmojib M, Konetschny C, Grillberger L, Reiter M. Avian cell line - Technology for large scale vaccine production. BMC Proc. 2011;5(Suppl 8):52.
   Google Scholar
• Nikolay A, Leon A, Schwamborn K, Genzel Y, Reichl U. Process intensification of EB66(R) cell cultivations leads to high-yield yellow fever and Zika virus production. Appl Microbiol Biotechnol. 2018;102:8725–37.
   PubMed Web of Science ®Google Scholar
• Organization WH Types of seasonal influenza vaccine. World Health Organization. [accessed 2021 Jan 6]. https://www.euro.who.int/en/health-topics/communicable-diseases/influenza/vaccination/types-of-seasonal-influenza-vaccine .
   Google Scholar
• Ishikawa T, Yamanaka A, Konishi E. A review of successful flavivirus vaccines and the problems with those flaviviruses for which vaccines are not yet available. Vaccine. 2014;32:1326–37.
   PubMed Web of Science ®Google Scholar
• Collins MH, Metz SW. Progress and works in progress: update on flavivirus vaccine development. Clin Ther. 2017;39:1519–36.
   PubMed Web of Science ®Google Scholar
• Temporary total depletion of US licensed yellow fever vaccine addressed by availability of stamaril vaccine at selected clinics. Centers for Disease Control and Prevention, 2020 [accessed 2020 Nov 6]. https://wwwnc.cdc.gov/travel/news-announcements/yellow-fever-vaccine-access.
   Google Scholar
• Yellow Fever Vaccine Information. Sanofi U.S., 2020[accessed 2020 Nov 6]. https://www.sanofi.us/en/products-and-resources/vaccines/yellow-fever-vaccine-information#:~:text=Sanofi%20Pasteur’s%20new%20U.S.%20YF,YF%2DVAX%20in%20December%202020 .
   Google Scholar
• Wilder-Smith A. Yellow fever vaccination: estimating coverage. Lancet Infect Dis. 2017;17:1109–11.
   PubMed Web of Science ®Google Scholar
• Yellow fever global vaccine stockpile in emergencies. World Health Organization, 2016 [accessed 2020 Apr 3]. https://www.who.int/news-room/feature-stories/detail/yellow-fever-global-vaccine-stockpile-in-emergencies: .
   Google Scholar
• Vannice K, Wilder-Smith A, Fractional-Dose Yellow HJ. Fever vaccination — advancing the evidence base. N Engl J Med. 2018;379.
   Web of Science ®Google Scholar
• The L. Yellow fever: a major threat to public health. Lancet. 2018;391:402.
   Web of Science ®Google Scholar
• Da Costa-rocha IA, Campi-Azevedo AC, Peruhype-Magalhaes V, Coelho-Dos-Reis JG, Fradico JRB, Souza-Lopes T, Reis LR, Freire LC, Costa-Pereira C, Mambrini JVM, et al. Duration of humoral and cellular immunity 8 years after administration of reduced doses of the 17DD-Yellow fever vaccine. Front Immunol. 2019;10:1211.
   PubMed Web of Science ®Google Scholar
• Roukens AHE, Van Halem K, De Visser AW, Visser LG. Long-term protection after fractional-dose yellow fever vaccination: follow-up study of a randomized, controlled, noninferiority trial. Ann Intern Med. 2018;169:761–65.
   PubMed Web of Science ®Google Scholar
• Callender DM. Management and control of yellow fever virus: Brazilian outbreak January-April, 2018. Glob Public Health. 2019;14:445–55.
   PubMed Web of Science ®Google Scholar
• Gotuzzo E, Yactayo S, Cordova E. Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years. Am J Trop Med Hyg. 2013;89:434–44.
   PubMed Web of Science ®Google Scholar
• Roukens AHE, Visser LG. Fractional-dose yellow fever vaccination: an expert review. J Travel Med. 2019;26.
   Web of Science ®Google Scholar
• Wilder-Smith A, Leong WY. Importation of yellow fever into China: assessing travel patterns. J Travel Med. 2017;24.
   Web of Science ®Google Scholar
• World Tourism Organization, World Bank. Yearbook of tourism statistics. International arrivals. World Tourism Organization. [accessed 2020 Apr 3]. https://data.worldbank.org/indicator/st.int.arvl .
   Google Scholar
• Kraemer MU, Sinka ME, Duda KA, Mylne AQ, Shearer FM, Barker CM, Moore CG, Carvalho RG, Coelho GE, Van Bortel W, et al. The global distribution of the arbovirus vectors Aedes aegypti and Ae. Albopictus. Elife. 2015;4:e08347.
   PubMed Web of Science ®Google Scholar
• WHO report on global surveillance of epidemic-prone infectious diseases - Yellow fever. Emergencies preparedness, response. World health Organization. https://www.who.int/csr/resources/publications/yellowfev/CSR_ISR_2000_1/en/index1.html .
   Google Scholar
• Liu-Helmersson J, Brannstrom A, Sewe MO, Semenza JC, Estimating Past RJ. Present, and future trends in the global distribution and abundance of the arbovirus vector aedes aegypti under climate change scenarios. Front Public Health. 2019;7:148.
   PubMed Web of Science ®Google Scholar
• Pereira RC, Silva AN, Souza MC, Silva MV, Neves PP, Silva AA, Matos DD, Herrera MA, Yamamura AM, Freire MS, et al. An inactivated yellow fever 17DD vaccine cultivated in Vero cell cultures. Vaccine. 2015;33:4261–68.
   PubMed Web of Science ®Google Scholar
• Pugachev KV, Guirakhoo F, Monath TP. New developments in flavivirus vaccines with special attention to yellow fever. Curr Opin Infect Dis. 2005;18:387–94.
   PubMed Web of Science ®Google Scholar
• Julander JG, Trent DW, Monath TP. Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model. Vaccine. 2011;29:6008–16.
   PubMed Web of Science ®Google Scholar
• Monath TP, Fowler E, Johnson CT, Balser J, Morin MJ, Sisti M, Trent DW. An inactivated cell-culture vaccine against yellow fever. N Engl J Med. 2011;364:1326–33.
   PubMed Web of Science ®Google Scholar
• Hayes EB. Is it time for a new yellow fever vaccine? Vaccine. 2010;28:8073–76.
   PubMed Web of Science ®Google Scholar
• Tretyakova I, Nickols B, Hidajat R, Jokinen J, Lukashevich IS, Plasmid PP. DNA initiates replication of yellow fever vaccine in vitro and elicits virus-specific immune response in mice. Virology. 2014;468-470:28–35.
   PubMed Web of Science ®Google Scholar
• Jiang X, Dalebout TJ, Lukashevich IS, Bredenbeek PJ, Franco D. Molecular and immunological characterization of a DNA-launched yellow fever virus 17D infectious clone. J Gen Virol. 2015;96:804–14.
   PubMed Web of Science ®Google Scholar
• Pushko P, Lukashevich IS, Weaver SC, Tretyakova I. DNA-launched live-attenuated vaccines for biodefense applications. Expert Rev Vaccines. 2016;15:1223–34.
   PubMed Web of Science ®Google Scholar
• Maciel M Jr., Cruz Fda S, Cordeiro MT, Da Motta MA, Cassemiro KM, Maia Rde C, de Figueiredo RC, Galler R, Freire Mda S, August JT, et al. A DNA vaccine against yellow fever virus: development and evaluation. PLoS Negl Trop Dis. 2015;9:e0003693.
   PubMed Web of Science ®Google Scholar
• Safety and immunogenicity study of 2019-nCoV vaccine (mRNA-1273) for prophylaxis of SARS-CoV-2 infection (COVID-19). ClinicalTrials.gov, NIH U.S. National Library fo Medicine, 2020 [accessed 2020 Oct 13]. https://clinicaltrials.gov/ct2/show/NCT04283461 .
   Google Scholar
• Erasmus JH, Fuller DH. Preparing for pandemics: RNA Vaccines at the forefront. Mol Ther. 2020;28:1559–60.
   PubMed Web of Science ®Google Scholar
• Fuller DH, Berglund P. Amplifying RNA Vaccine Development. N Engl J Med. 2020;382:2469–71.
   PubMed Web of Science ®Google Scholar
• Self-Amplifying LK. RNA Viruses as RNA Vaccines. Int J Mol Sci. 2020;21.
   Web of Science ®Google Scholar
• Julander JG, Testori M, Cheminay C, Volkmann A. Immunogenicity and protection after vaccination with a modified vaccinia virus ankara-vectored yellow fever vaccine in the Hamster model. Front Immunol. 2018;9:1756.
   PubMed Web of Science ®Google Scholar
• Priyamvada L, Hudson W, Ahmed R, Wrammert J. Humoral cross-reactivity between Zika and dengue viruses: implications for protection and pathology. Emerg Microbes Infect. 2017;6:e33.
   PubMed Web of Science ®Google Scholar
• A phase I trial to evaluate the safety, reactogenicity, and immunogenicity of MVA-BN yellow fever vaccine with and without montanide ISA-720 adjuvant in 18-45 year old healthy volunteers (NCT02743455). ClinicalTrials.gov, NIH U.S. National Library fo Medicine, 2016 [accessed 2020 Apr 3]. https://clinicaltrials.gov/ct2/show/NCT02743455 .
   Google Scholar
• Schafer B, Holzer GW, Joachimsthaler A, Coulibaly S, Schwendinger M, Crowe BA, Kreil TR, Barrett PN, Falkner FG. Pre-clinical efficacy and safety of experimental vaccines based on non-replicating vaccinia vectors against yellow fever. PLoS One. 2011;6:e24505.
   PubMed Web of Science ®Google Scholar
• Rollier CS, Reyes-Sandoval A, Cottingham MG, Ewer K, Hill AV. Viral vectors as vaccine platforms: deployment in sight. Curr Opin Immunol. 2011;23:377–82.
   PubMed Web of Science ®Google Scholar
• Imler JL. Adenovirus vectors as recombinant viral vaccines. Vaccine. 1995;13:1143–51.
   PubMed Web of Science ®Google Scholar
• Schwartz DA. Being pregnant during the Kivu Ebola virus outbreak in DR Congo: the rVSV-ZEBOV vaccine and its accessibility by mothers and infants during humanitarian crises and in conflict areas. Vaccines (Basel). 2020;8.
   PubMed Web of Science ®Google Scholar
• Effectiveness and safety of a heterologous, two-dose Ebola vaccine in the DRC. ClinicalTrials.gov, NIH U.S. National Library fo Medicine, 2019 [accessed 2020 Oct 14]. https://clinicaltrials.gov/ct2/show/NCT04152486?term=Ad26.ZEBOV%2FMVA-BN-Filo&cond=Ebola&cntry=CD&draw=2&rank=2 .
   Google Scholar
• Kim YC, Dema B, Reyes-Sandoval ACOVID-19. vaccines: breaking record times to first-in-human trials. NPJ Vaccines. 2020;5:34.
   PubMed Web of Science ®Google Scholar
• A study of a candidate COVID-19 vaccine (COV001). ClinicalTrials.gov, NIH U.S. National Library fo Medicine, 2020 [accessed 2020 May 18]. https://clinicaltrials.gov/ct2/show/NCT04324606 .
   Google Scholar
• Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, Bellamy D, Bibi S, Bittaye M, Clutterbuck EA, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396:467–78.
   PubMed Web of Science ®Google Scholar
• Lopez-Camacho C, Abbink P, Larocca RA, Dejnirattisai W, Boyd M, Badamchi-Zadeh A, Wallace ZR, Doig J, Velazquez RS, Neto RDL, et al. Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpanzee adenoviral vectors. Nat Commun. 2018;9:2441.
   PubMed Web of Science ®Google Scholar
• Safety and immunogenicity of a candidate ZIKV vaccine (ZIKA001). ClinicalTrials.gov, NIH U.S. National Library fo Medicine, 2019 [accessed 2020 Apr 3]. https://clinicaltrials.gov/ct2/show/NCT04015648 .
   Google Scholar
• Dicks MD, Spencer AJ, Edwards NJ, Wadell G, Bojang K, Gilbert SC,Hill AV, Cottingham MG. A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity. PLoS One. 2012;7:e40385.
   PubMed Web of Science ®Google Scholar
• Fausther-Bovendo H, Kobinger GP. Pre-existing immunity against Ad vectors: humoral, cellular, and innate response, what’s important? Hum Vaccin Immunother. 2014;10:2875–84.
   PubMed Web of Science ®Google Scholar
• Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99–111.
   PubMed Web of Science ®Google Scholar
• Immunization Schedules - Africa. University of Cape Town. [accessed 2021 Jan 17]. http://www.vacfa.uct.ac.za/immunization-schedules-africa .
   Google Scholar
• Gouglas D, Thanh Le T, Henderson K, Kaloudis A, Danielsen T, Hammersland NC,Robinson JM, Heaton PM, Rottingen JA. Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation study. Lancet Glob Health. 2018;6:e1386–e96.
   PubMed Web of Science ®Google Scholar